Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting Secondary and Tertiary Resistance to BRAF Inhibition in BRAF V600E-Mutated Metastatic Colorectal Cancer.

JCO precision oncology - 1 Nov 2021

Akhoundova Dilara, Pietge Heike, Hussung Saskia, Kiessling Michael, Britschgi Christian, Zoche Martin, Rechsteiner Markus, Weber Achim, Fritsch Ralph M

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Colorectal Neoplasms
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 34994629
DOI: 10.1200/PO.21.00107

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting Secondary and Tertiary Resistance to BRAF Inhibition in BRAF V600E-Mutated Metastatic Colorectal Cancer.PMID 34994629Read ↗

The past, present, and future treatment of BRAFV600-mutant metastatic colorectal cancer: A comprehensive review.Semantic proximity Read ↗

BRAF-Directed Therapy in Metastatic Colorectal Cancer.Semantic proximity Read ↗

BRAFV600E-Mutant Metastatic Colorectal Cancer: Current Evidence, Future Directions, and Research Priorities.Semantic proximity Read ↗

New therapeutic strategies for BRAF mutant colorectal cancers.Semantic proximity Read ↗

Improvements in Clinical Outcomes for BRAFV600E -Mutant Metastatic Colorectal Cancer.Semantic proximity Read ↗

Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era.Semantic proximity Read ↗

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights.Semantic proximity Read ↗

From poor prognosis to precision promise: Clinical trials targeting BRAF-mutant metastatic colorectal cancer.Semantic proximity Read ↗

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?Semantic proximity Read ↗

Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies.Semantic proximity Read ↗

The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancerSemantic proximity Read ↗

Colorectal cancer: Targeting BRAF mutations equally?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.